HIV臨床試驗市場－全球產業規模、佔有率、趨勢、機會、預測：按階段、研究設計、申辦者、地區和競爭對手分類，2021-2031年

全球 HIV 臨床試驗市場預計將從 2025 年的 16.7 億美元成長到 2031 年的 23.2 億美元，複合年成長率為 5.63%。

這些試驗包括旨在評估用於治療或預防人類免疫力缺乏病毒（HIV）的藥物和行為干預措施的安全性和有效性的系統性研究。該市場的主要驅動力是HIV感染在全球範圍內的持續蔓延，這使得開發創新抗逆轉錄病毒療法和有效疫苗的需求持續存在。全球衛生組織和政府機構為實現病毒抑制目標提供了大量資金支持，從而推動了這項需求。根據聯合國愛滋病規劃署（UNAIDS）2024年的報告，全球約有4,080萬人感染HIV，凸顯了持續推動治療方法和提供可近性治療方案的重要性。

然而，在醫療基礎設施不足的地區，我們在招募和留住病患方面面臨巨大的挑戰。確保參與者長期持續參與的後勤難題常常導致營運延誤和成本增加。這些問題會阻礙關鍵臨床試驗的順利進行，並成為開發重要新治療方法的障礙。

市場促進因素

長效注射抗逆轉錄病毒療法的研發正在改變該領域的格局，解決了每日口服藥物帶來的許多挑戰。製藥公司正積極優先研發緩釋製劑，以提供更便利的給藥方案，進而提高臨床試驗和真實世界研究中的病患遵從率。吉利德科學公司於2024年7月宣布“吉利德在研的每年兩次給藥的瑞那卡帕韋（Renacapavir）的完整療效和安全性結果”，這是該領域的一項重大進展。在3期PURPOSE 1試驗中，瑞那卡帕韋對未確診感染的順性別女性顯示100%的療效。這種降低給藥頻率的措施不僅有助於改善治療效果，而且隨著競爭對手致力於研發給藥間隔長達數月的製劑，也為臨床研發注入了新的活力。

同時，人們也正致力於功能性修復和基因療法的研究，以實現持續的病毒抑制。該研究舉措重點關注廣譜中和抗體等創新方法，並獲得了早期通訊協定的大力資助。如同治療行動小組（TAG）於2024年7月發布的《2024年研發管線報告》所述，隨著艾伯維公司啟動其II期臨床試驗（140名受試者），研究範圍正在擴大。該試驗將是迄今為止規模最大的HIV治療相關介入試驗，並設有分析性治療終止期。儘管取得了這些科學進展，但持續高企的感染率凸顯了這些研究的重要性。根據聯合國愛滋病規劃署的數據，2024年全球將新增約130萬HIV感染者，這再次表明，在預防和治療方面的臨床研究需要不斷創新。

市場挑戰

全球愛滋病臨床試驗市場面臨的一大障礙是醫療基礎設施不足地區招募和留住病患的難度。進行嚴謹的研究需要配備可靠的醫療設備、穩定的供應鏈和訓練有素的醫護人員，以確保資料的完整性和受試者的安全。然而，在許多愛滋病感染率高的地區，這些基本要素往往缺失或無法可靠保障。基礎設施的匱乏使得試驗管理困難重重，導致受試者脫落率增加和研究週期延長。因此，製藥公司面臨營運成本增加和新治療方法上市時間顯著延遲的雙重困境，這直接阻礙了該行業的成長潛力。

造成這種營運不穩定的根本原因在於資源嚴重匱乏，阻礙了關鍵基礎設施的發展。 2024年，聯合國愛滋病規劃署（UNAIDS）報告稱，在低收入和中等收入國家，有效控制愛滋病所需的資金籌措目標金額與實際籌集到的愛滋病防治資金之間存在約95億美元的缺口。這一資金缺口限制了當地醫療衛生系統滿足臨床研究高要求的能力。除非投入足夠的資金來加強這些醫療衛生系統，否則市場在進行開發下一代愛滋病治療方法所需的大規模、多樣化試驗方面將繼續面臨挑戰。

市場趨勢

在患者分層和保留方面應用人工智慧 (AI) 正成為解決該領域參與者管理長期低效問題的關鍵趨勢。隨著複雜的機器學習演算法擴大用於分析海量資料集，研究人員能夠以驚人的準確度預測患者的用藥依從性模式並最佳化隊列選擇。這種技術整合有助於及早識別高風險族群，從而直接降低長期研究中常見的較高脫落率。美國國立衛生Meta分析(NIH) 在 2025 年 2 月發布的綜述《人工智慧在 HIV 研究中的應用：進展與未來方向》中重點介紹了一項對 401,389 名 HIV 感染者進行的薈萃分析，該分析表明這些模型具有顯著提高大規模臨床試驗決策和預測準確性的潛力。

同時，市場顯然優先考慮兒童和青少年製劑的臨床試驗，旨在彌合先前被排除在基礎研究之外的年輕一代在治療選擇方面的差距。投資者和相關人員正集中資金開發適合不同年齡層的干涉措施，例如針對正在發育的免疫系統量身定做的疫苗和緩釋療法。這一趨勢源於迫切需要為需要終身管理計劃的嬰兒童提供公平的醫療保健標準。根據威爾康奈爾醫學院2025年9月發布的題為「美國國立衛生研究院津貼旨在開發兒童HIV疫苗」的新聞稿，一個多機構研究小組已獲得2080萬美元的津貼，用於推進一種專門為兒童臨床試驗設計的實驗性HIV疫苗的臨床前開發和完善工作。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球愛滋病臨床試驗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 階段（第一階段、第二階段、第三階段、第四階段）
  • 依研究設計進行的研究（介入研究、觀察性研究、擴大使用研究）
  • 贊助商（製藥和生物製藥公司、非營利組織、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美愛滋病臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲愛滋病臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區愛滋病臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲愛滋病臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲愛滋病臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球愛滋病臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• Syneos Health Inc
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global HIV Clinical Trials Market is projected to expand from USD 1.67 Billion in 2025 to USD 2.32 Billion by 2031, registering a CAGR of 5.63%. These trials involve systematic research aimed at assessing the safety and effectiveness of pharmaceutical and behavioral interventions designed to treat or prevent the Human Immunodeficiency Virus. The primary driver for this market is the enduring global prevalence of the infection, which creates a continuous need for innovative antiretroviral therapies and the development of viable vaccines. This demand is supported by significant financial backing from international health organizations and government bodies striving to reach viral suppression goals. As reported by UNAIDS in 2024, roughly 40.8 million individuals were living with HIV worldwide, highlighting the vital necessity for ongoing therapeutic progress and accessible treatment solutions.

However, the industry faces substantial hurdles related to the difficulties of recruiting and retaining patients in areas with inadequate healthcare infrastructure. The logistical challenges involved in ensuring consistent participant engagement over long durations frequently result in operational setbacks and escalating costs. These issues can hinder the efficient advancement of critical clinical studies, posing a barrier to the timely development of essential new interventions.

Market Driver

The landscape of the sector is being transformed by the creation of long-acting injectable antiretroviral therapies, which solve key issues related to adhering to daily oral medication. Pharmaceutical firms are actively prioritizing extended-release options that provide more convenient dosing schedules, which in turn boosts patient retention in both clinical trials and actual treatment settings. A significant breakthrough in this area was highlighted in a July 2024 press release by Gilead Sciences regarding the 'Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir'; the Phase 3 PURPOSE 1 trial showed that lenacapavir reached 100% efficacy with no infections found among cisgender women. This move toward less frequent dosing not only improves treatment results but also energizes the clinical pipeline as rivals work to create formulations with dosing gaps of several months.

At the same time, there is a heightened focus on investigating functional cures and gene therapies aimed at achieving sustained viral remission. Research initiatives are increasingly centering on innovative approaches like broadly neutralizing antibodies, backed by strong funding for early-stage protocols. As noted by the Treatment Action Group in their '2024 Pipeline Report' from July 2024, the research field has broadened with the start of an AbbVie Phase II study enrolling 140 participants, marking it as the largest HIV cure-related interventional trial to date involving analytical treatment interruption. Even with these scientific advances, the ongoing transmission rates emphasize the critical need for such studies; UNAIDS reported that in 2024, about 1.3 million people were newly infected with HIV worldwide, confirming the necessity for persistent innovation in preventative and curative clinical research.

Market Challenge

A major obstacle facing the Global HIV Clinical Trials Market is the difficulty of recruiting and retaining patients in regions with insufficient healthcare infrastructure. Performing rigorous studies necessitates sites equipped with dependable medical tools, steady supply chains, and skilled staff to guarantee data integrity and participant safety. However, in many areas with high HIV prevalence, these essential components are often missing or inconsistent. This infrastructure deficit makes the logistical handling of trials more difficult, resulting in high rates of participant dropout and prolonged study durations. As a result, pharmaceutical companies encounter higher operational expenses and substantial delays in introducing new therapies, which directly impedes the growth potential of the sector.

Severe resource limitations that hinder essential infrastructural improvements are the root cause of this operational instability. UNAIDS reported in 2024 that there was a funding gap of approximately USD 9.5 billion between the available resources for HIV responses in low- and middle-income nations and the targets needed for effective disease management. This lack of funds restricts the capacity of local health systems to meet the rigorous demands of clinical research. Unless there is sufficient investment to strengthen these healthcare structures, the market will continue to face challenges in conducting the large-scale, diverse trials required to develop the next generation of HIV treatments.

Market Trends

The use of Artificial Intelligence for patient stratification and retention is becoming a pivotal trend, tackling long-standing inefficiencies in managing participants within the sector. Sophisticated machine learning algorithms are increasingly utilized to examine immense datasets, allowing researchers to forecast patient adherence patterns and refine cohort selection with remarkable accuracy. This integration of technology directly helps reduce the high dropout rates typical of long-term studies by detecting at-risk individuals early on. As highlighted in a February 2025 review by the National Institutes of Health titled 'AI applications in HIV research: advances and future directions', a meta-analysis of 401,389 people living with HIV showed that these models have the potential to vastly improve clinical decision-making and predictive precision in large-scale trials.

At the same time, the market is seeing a clear emphasis on trials for pediatric and adolescent-specific formulations, aiming to bridge the therapeutic gap for younger groups that have historically been left out of primary research. Investors and stakeholders are channeling more funds into creating age-appropriate interventions, including vaccines and long-acting treatments customized for developing immune systems. This trend is motivated by the critical necessity of offering equitable standards of care for infants and children needing lifelong management plans. According to a September 2025 news release from Weill Cornell Medicine regarding the 'NIH Grant Aims for Childhood Vaccine Against HIV', a multi-institutional group received a $20.8 million grant to further the preclinical development and refinement of an experimental HIV vaccine tailored specifically for pediatric clinical trials.

Key Market Players

• PPD Inc
• IQVIA Inc
• PAREXEL International Corp
• ICON PLC
• Syneos Health Inc
• WuXi AppTec Co Ltd
• Janssen Global Services LLC
• Gilead Sciences Inc
• GSK PLC
• Charles River Laboratories Inc

Report Scope

In this report, the Global HIV Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HIV Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

HIV Clinical Trials Market, By Study Design

• Interventional Studies
• Observational Studies
• Expanded Access Studies

HIV Clinical Trials Market, By Sponsor

• Pharmaceutical & Biopharmaceutical Companies
• Non-Profit Organizations
• Others

HIV Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HIV Clinical Trials Market.

Available Customizations:

Global HIV Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HIV Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies)
  • 5.2.3. By Sponsor (Pharmaceutical & Biopharmaceutical Companies, Non-Profit Organizations, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America HIV Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Sponsor
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States HIV Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Sponsor
  • 6.3.2. Canada HIV Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Sponsor
  • 6.3.3. Mexico HIV Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Sponsor

7. Europe HIV Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Sponsor
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany HIV Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Sponsor
  • 7.3.2. France HIV Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Sponsor
  • 7.3.3. United Kingdom HIV Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Sponsor
  • 7.3.4. Italy HIV Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Sponsor
  • 7.3.5. Spain HIV Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Sponsor

8. Asia Pacific HIV Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Sponsor
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China HIV Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Sponsor
  • 8.3.2. India HIV Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Sponsor
  • 8.3.3. Japan HIV Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Sponsor
  • 8.3.4. South Korea HIV Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Sponsor
  • 8.3.5. Australia HIV Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Sponsor

9. Middle East & Africa HIV Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Sponsor
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia HIV Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Sponsor
  • 9.3.2. UAE HIV Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Sponsor
  • 9.3.3. South Africa HIV Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Sponsor

10. South America HIV Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Sponsor
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil HIV Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Sponsor
  • 10.3.2. Colombia HIV Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Sponsor
  • 10.3.3. Argentina HIV Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Sponsor

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global HIV Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. PPD Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. IQVIA Inc
• 15.3. PAREXEL International Corp
• 15.4. ICON PLC
• 15.5. Syneos Health Inc
• 15.6. WuXi AppTec Co Ltd
• 15.7. Janssen Global Services LLC
• 15.8. Gilead Sciences Inc
• 15.9. GSK PLC
• 15.10. Charles River Laboratories Inc

16. Strategic Recommendations

17. About Us & Disclaimer